Brought to you by 
Roche/Genentech get rights to SurModics' technology
14 Oct 2009
Executive Summary
SurModics (drug delivery, medical device coatings, and in vitro diagnostic components) has granted Roche and its Genentech division exclusive rights to apply its biodegradable microparticle drug delivery technology to create a sustained-release version of their wet AMD drug Lucentis (ranibizumab). The agreement also covers additional Genentech ophthalmic compounds.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Roche/Genentech get rights to SurModics' technology
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice